Kudo Masatoshi, Kawamura Yusuke, Hasegawa Kiyoshi, Tateishi Ryosuke, Kariyama Kazuya, Shiina Shuichiro, Toyoda Hidenori, Imai Yasuharu, Hiraoka Atsushi, Ikeda Masafumi, Izumi Namiki, Moriguchi Michihisa, Ogasawara Sadahisa, Minami Yasunori, Ueshima Kazuomi, Murakami Takamichi, Miyayama Shiro, Nakashima Osamu, Yano Hirohisa, Sakamoto Michiie, Hatano Etsuro, Shimada Mitsuo, Kokudo Norihiro, Mochida Satoshi, Takehara Tetsuo
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
Department of Hepatology, Toranomon Hospital, Tokyo, Japan.
Liver Cancer. 2021 Jun;10(3):181-223. doi: 10.1159/000514174. Epub 2021 May 19.
The Clinical Practice Manual for Hepatocellular Carcinoma was published based on evidence confirmed by the Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma along with consensus opinion among a Japan Society of Hepatology (JSH) expert panel on hepatocellular carcinoma (HCC). Since the JSH Clinical Practice Guidelines are based on original articles with extremely high levels of evidence, expert opinions on HCC management in clinical practice or consensus on newly developed treatments are not included. However, the practice manual incorporates the literature based on clinical data, expert opinion, and real-world clinical practice currently conducted in Japan to facilitate its use by clinicians. Alongside each revision of the JSH Guidelines, we issued an update to the manual, with the first edition of the manual published in 2007, the second edition in 2010, the third edition in 2015, and the fourth edition in 2020, which includes the 2017 edition of the JSH Guideline. This article is an excerpt from the fourth edition of the HCC Clinical Practice Manual focusing on pathology, diagnosis, and treatment of HCC. It is designed as a practical manual different from the latest version of the JSH Clinical Practice Guidelines. This practice manual was written by an expert panel from the JSH, with emphasis on the consensus statements and recommendations for the management of HCC proposed by the JSH expert panel. In this article, we included newly developed clinical practices that are relatively common among Japanese experts in this field, although all of their statements are not associated with a high level of evidence, but these practices are likely to be incorporated into guidelines in the future. To write this article, coauthors from different institutions drafted the content and then critically reviewed each other's work. The revised content was then critically reviewed by the Board of Directors and the Planning and Public Relations Committee of JSH before publication to confirm the consensus statements and recommendations. The consensus statements and recommendations presented in this report represent measures actually being conducted at the highest-level HCC treatment centers in Japan. We hope this article provides insight into the actual situation of HCC practice in Japan, thereby affecting the global practice pattern in the management of HCC.
《肝细胞癌临床实践手册》是依据《肝细胞癌循证临床实践指南》所证实的证据以及日本肝病学会（JSH）肝细胞癌（HCC）专家小组的共识意见而出版的。由于JSH临床实践指南基于具有极高证据水平的原始文章，因此未纳入临床实践中关于HCC管理的专家意见或新开发治疗方法的共识。然而，该实践手册纳入了基于临床数据、专家意见以及日本目前实际开展的临床实践的文献，以方便临床医生使用。随着JSH指南的每次修订，我们都会对手册进行更新，手册的第一版于2007年出版，第二版于2010年出版，第三版于2015年出版，第四版于2020年出版，其中包含2017年版的JSH指南。本文是《HCC临床实践手册》第四版的节选，重点关注HCC的病理学、诊断和治疗。它被设计为一本与最新版JSH临床实践指南不同的实用手册。本实践手册由JSH的专家小组编写，重点强调了JSH专家小组提出的HCC管理的共识声明和建议。在本文中，我们纳入了该领域日本专家中相对常见的新开发临床实践，尽管其所有声明并非都具有高水平的证据，但这些实践未来可能会被纳入指南。为撰写本文，来自不同机构的共同作者起草了内容，然后相互严格审查彼此的工作。修订后的内容在出版前由JSH董事会和规划与公共关系委员会进行严格审查，以确认共识声明和建议。本报告中提出的共识声明和建议代表了日本最高水平的HCC治疗中心实际正在采取的措施。我们希望本文能让大家深入了解日本HCC实践的实际情况，从而影响全球HCC管理的实践模式。
